Weekly · monthly · quarterly news summaries, side by side in time
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
First-half profit halved by price cuts and tax change Tiantan's first-half 2026 net profit fell about 52% to 299 million yuan, with revenue down 16.6%. The company blames medical insurance cost controls that sparked price competition in blood products, plus a January 2026 VAT change that raised its tax bill. Lower prices and higher taxes squeeze profit.
This is the core new financial result showing why the stock is under pressure.
Industry-wide price war and tax hit confirmed by peers Rival Weiguang Biological also reported a near-60% profit drop and is expanding capacity despite high inventory, signaling the whole blood-products sector is oversupplied and competing on price. This confirms Tiantan's troubles are industry-wide, not company-specific, and keeps pressure on its pricing and margins.
Shows the downturn is sector-wide, reinforcing the negative outlook for Tiantan's prices and volumes.
New hemophilia B drug clears Phase III trial Tiantan's subsidiary Chengdu Rongsheng completed Phase III testing of Human Coagulation Factor IX for hemophilia B and obtained the summary report. This moves a new product closer to market, which could add future revenue and reduce reliance on older products facing price pressure.
A new pipeline advance is the main positive development this period that could support the stock.
First-half profit halved by price cuts and tax change Tiantan's first-half 2026 net profit fell about 52% to 299 million yuan, with revenue down 16.6%. The company blames medical insurance cost controls that sparked price competition in blood products, plus a January 2026 VAT change that raised its tax bill. Lower prices and higher taxes squeeze profit.
This is the core new financial result showing why the stock is under pressure.
Industry-wide price war and tax hit confirmed by peers Rival Weiguang Biological also reported a near-60% profit drop and is expanding capacity despite high inventory, signaling the whole blood-products sector is oversupplied and competing on price. This confirms Tiantan's troubles are industry-wide, not company-specific, and keeps pressure on its pricing and margins.
Shows the downturn is sector-wide, reinforcing the negative outlook for Tiantan's prices and volumes.
New hemophilia B drug clears Phase III trial Tiantan's subsidiary Chengdu Rongsheng completed Phase III testing of Human Coagulation Factor IX for hemophilia B and obtained the summary report. This moves a new product closer to market, which could add future revenue and reduce reliance on older products facing price pressure.
A new pipeline advance is the main positive development this period that could support the stock.
First-half profit halved by price cuts and tax change Tiantan's first-half 2026 net profit fell about 52% to 299 million yuan, with revenue down 16.6%. The company blames medical insurance cost controls that sparked price competition in blood products, plus a January 2026 VAT change that raised its tax bill. Lower prices and higher taxes squeeze profit.
This is the core new financial result showing why the stock is under pressure.
Industry-wide price war and tax hit confirmed by peers Rival Weiguang Biological also reported a near-60% profit drop and is expanding capacity despite high inventory, signaling the whole blood-products sector is oversupplied and competing on price. This confirms Tiantan's troubles are industry-wide, not company-specific, and keeps pressure on its pricing and margins.
Shows the downturn is sector-wide, reinforcing the negative outlook for Tiantan's prices and volumes.
New hemophilia B drug clears Phase III trial Tiantan's subsidiary Chengdu Rongsheng completed Phase III testing of Human Coagulation Factor IX for hemophilia B and obtained the summary report. This moves a new product closer to market, which could add future revenue and reduce reliance on older products facing price pressure.
A new pipeline advance is the main positive development this period that could support the stock.